AstraZeneca PLC (LON:AZN)
Market Cap | 161.82B |
Revenue (ttm) | 42.56B |
Net Income (ttm) | 6.02B |
Shares Out | 1.55B |
EPS (ttm) | 3.85 |
PE Ratio | 27.13 |
Forward PE | 15.13 |
Dividend | 2.36 (2.26%) |
Ex-Dividend Date | Feb 20, 2025 |
Volume | 1,135,289 |
Average Volume | 2,410,362 |
Open | 10,490 |
Previous Close | 10,436 |
Day's Range | 10,464 - 10,598 |
52-Week Range | 9,574 - 13,388 |
Beta | 0.18 |
RSI | 51.77 |
Earnings Date | Apr 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial numbers in USD Financial StatementsNews
AstraZeneca wins EU backing for Imfinzi in bladder cancer
Why AstraZeneca May Be 2025's Most Underrated Pharma Stock

Aptar Digital Health Announces Licensing Agreement With AstraZeneca to Develop AI-Powered Screening Algorithms
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Digital Health and AstraZeneca announce licensing agreement to develop AI-powered screening algorithms for early disease detection.
AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
SERENA-6 plenary presentation will feature next-generation oral SERD camizestrant in 1st-line advanced HR-positive breast cancer MATTERHORN plenary presentation will showcase perioperative treatment w...

AstraZeneca's record seventh year of plenary data at ASCO furthers ambition to redefine breast cancer care and transform outcomes in gastric cancer
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American S...
AstraZeneca touts new Airsupra data for asthma rescue

Statistically significant and clinically meaningful BATURA Phase III trial results provide new evidence for AIRSUPRA as standard of care for as-needed rescue treatment in asthma
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the BATURA Phase IIIb trial showed AstraZeneca's anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated ...

Market shake-up: Tech edges up while energy and consumer stocks drag
Sector Overview The US stock market today exhibits a diversified portfolio of trends, as revealed by the latest heatmap snapshot. Technology stands out marginally in the green, while energy and major ...

35 Barron's Pro-Picks: One Ideal May DiviDog
Barron's interviewed eleven financial industry Roundtable-pros who tapped 65 predictions. Six non-ADR foreign-stocks and four mutual funds were dropped by YCharts screens of active US listings, leavin...
Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers
Study also met secondary endpoint of overall survival (OS) for patients whose tumors express PD-L1 KEYTRUDA ® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first im...

P/E Ratio Insights for AstraZeneca
In the current session, AstraZeneca Inc. (NASDAQ: AZN) is trading at $66.27, after a 2.14% drop. Over the past month, the stock decreased by 1.16% , and in the past year, by 13.98% . With performance...

BioInvent Announces Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the Treatment of Non-Hodgkin's Lymphoma
Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical respo...

AstraZeneca to showcase latest research on comprehensive portfolio and pipeline aimed at transforming respiratory diseases at ATS 2025
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca will present the latest clinical and real-world data across its leading inhaled, biologic and early science respiratory portfolio at the American Thoraci...

AstraZeneca and GSK in the firing line as Trump targets big pharma: ALEX BRUMMER
No one expected US peace in our time at the Geneva talks with China at the weekend, but what emerged is better than predicted.
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices
Novo Nordisk, which generates around 60% of its sales in the U.S., is among the biggest losers in early European trade.

Pharmaceutical stocks slide as Trump vows to cut US prescription drug prices ‘by 30-80%'
President plans to use executive powers, saying US should pay ‘same price as nation that pays the lowest price'
AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Changes | AZN Stock News
AstraZeneca (AZN) Faces Market Uncertainty Amid Drug Pricing Changes | AZN Stock News
AstraZeneca's bladder cancer treatment shows positive results in trial

IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG inductio...
AstraZeneca, Daiichi post late-stage trial win for Enhertu in early-stage breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11
AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive ...

Tempus AI Strikes $200M Deal With AstraZeneca, Pathos To Build World's Largest Oncology Model
Tempus AI Inc. (NASDAQ: TEM) during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” What Happened: During its first-quarter earning...
ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results ...